How to Know If You're in Perimenopause — and What a Test Can't Tell You

Quick answer: At 45 and over there is no blood test that confirms perimenopause, and the guidance tells clinicians not to order one. What identifies it is your age, your symptoms and what your cycles have been doing, which puts the most useful instrument in your own hands: a record of the dates your periods start. Below 45 the question changes and so does the answer. Testing also has a second, separate job, which is ruling out the conditions that produce the same symptoms.

What follows is the self-check in full, the age rules written out as the guidelines write them, and the situation most pages skip: how to work it out when contraception or surgery has taken away the evidence everything else depends on.

Is there a test for perimenopause?

No, not in the sense of one result that settles it, and above 45 the guidance is explicit that none is needed. NICE instructs clinicians to identify perimenopause "without laboratory tests" in otherwise healthy people aged 45 or over who have menopause-associated symptoms, where vasomotor symptoms "have recently started" and there are "any changes in their menstrual cycle" (NICE NG23, 1.3.1, last updated 15 April 2026).

Cleveland Clinic says the same thing from the clinic side, and gives the reason: "Hormone testing isn't necessary to diagnose perimenopause. Hormone levels fluctuate so much that the tests aren't reliable." A provider instead determines that you're transitioning to menopause "based on a physical exam and your symptoms, age and medical history" (Cleveland Clinic).

Nor is there a scan: "There aren't any imaging tests that can confirm perimenopause," though a provider "may order tests to rule out other conditions" (Cleveland Clinic). The NIA is equally blunt about the difficulty: "It may be difficult for you and your doctor to tell whether you are in the menopausal transition" (NIA).

Why a hormone test can't tell you

This is not a matter of test quality or lab accuracy. The lab can measure your follicle-stimulating hormone perfectly well. The problem is what that measurement means in a process defined by instability.

The staging system specialists use — the Stages of Reproductive Aging Workshop +10, or STRAW+10 — describes early-transition FSH as "elevated but variable" (Harlow et al., 2012). Variability isn't noise around the signal. It is the signal. And it grows more pronounced later, not less: in the late transition, FSH levels are "sometimes elevated into the menopausal range and sometimes within the range characteristic of the earlier reproductive years" (Harlow et al., 2012).

The same woman, in the same stage, can produce a menopausal-looking result or an unremarkable one depending on the morning you catch her. Cleveland Clinic makes the point clinically: a consistently high FSH can indicate you're getting near menopause, "but FSH tests can be misleading because during perimenopause, your hormones rise and fall erratically" (Cleveland Clinic). Note the word consistently. One test cannot demonstrate it.

Other things move these numbers too. Cleveland Clinic notes that "certain medications and health conditions interfere with hormone levels," hormonal contraception being the obvious one at this age (Cleveland Clinic).

A self-check you can actually run

The record that answers the question is smaller than most people expect: the date each period starts, how long the bleeding lasts, and a line about what else has changed. The Office on Women's Health gives the instruction in three words — "Track your periods" — and adds that irregular periods "may be your first sign of menopause" (OWH).

What to record

• Cycle length, measured start to start. First day of bleeding to the first day of the next bleed, not the number of bleeding days. STRAW+10's criteria compare consecutive cycles, so one length on its own tells you nothing.
• What changed, and when it started. NICE's identification rule turns on vasomotor symptoms that "have recently started," so the date matters as much as the symptom (NICE NG23, 1.3.1). Hot flashes, night sweats, sleep, mood, and how the bleeding compares with your own normal. Which of those symptoms actually narrow the question down is worth knowing before you write a long list.
• Anything on the report-it list below, which does not wait for the record to be finished.

How long to keep it

Three period start dates give you two cycle lengths, which is the minimum for the comparison the criteria are built on. After that the honest answer depends on what the first comparison shows, because STRAW+10 does not count a single odd month: it defines persistence as "recurrence within 10 cycles of the first variable length cycle" (Harlow et al., 2012). A swing that repeats inside those ten cycles meets the threshold; one that doesn't, doesn't. That arithmetic comes from the published definitions rather than from any recommendation about how long to keep a diary, and no guideline read for this page sets a diary length.

You do not have to finish the record before making an appointment. If you are 45 or over with recently started hot flashes and any change in your cycle, NICE's rule is already satisfied without a test or a diary (NICE NG23, 1.3.1). The log is what makes the conversation specific, not a precondition for having it.

Reading what you've written down

Those first two thresholds are also the ones that place you in a stage, so the same dates answer two questions at once: whether this is the transition, and how far through it you are. Working out which stage of the transition you're in takes the second one in detail.

What doesn't wait for the record

Some bleeding patterns are reported rather than logged, whatever perimenopause seems to explain. Cleveland Clinic names them: periods that become very heavy or contain large clots, changing a pad or tampon every one to two hours, periods lasting several days longer than usual, spotting or bleeding between periods, bleeding after sex, and periods occurring less than 21 days apart (Cleveland Clinic). The causes a provider will be thinking about include infection, fibroids, blood clotting disorders, polyps and cancer, which is why the appointment comes before the next month of tracking.

Any bleeding at all more than 12 months after your last period belongs in the same category. The NHS asks you to have it checked "even if it's only happened once," even if it is "only a small amount of blood, spotting, or pink or brown discharge," and even if you have no other symptoms, because postmenopausal bleeding "is not usually serious but can be a sign of cancer" (NHS).

Then bring the record to an appointment. Six or twelve documented cycles give a clinician something a one-off hormone level cannot, and they turn I think something's changing into a pattern someone can work with.

Age changes the answer

Age decides what a test is being asked to settle, which is why the same blood draw is part of a diagnosis at 38 and discouraged at 48. NICE sets out three rules, one for each band.

At 45 and over, NICE NG23 recommendation 1.3.1 tells clinicians to identify perimenopause without laboratory tests in otherwise healthy people who have menopause-associated symptoms, specifically recently started vasomotor symptoms together with any change in the menstrual cycle.

Between 40 and 45, NICE NG23 recommendation 1.3.6 says to consider using a serum FSH level to confirm menopause only in people with menopause-associated symptoms including a change in their menstrual cycle.

Under 40, NICE NG23 recommendations 1.7.2 and 1.7.3 diagnose premature ovarian insufficiency from menopause-associated symptoms together with "elevated follicle stimulating hormone (FSH) levels on 2 blood samples taken 4 to 6 weeks apart," and add: "Do not diagnose premature ovarian insufficiency on the basis of a single blood test."

A detail inside that table is easy to miss, and NICE does not flag it: its own two age bands are not the same band. Recommendation 1.2.7 defines early menopause as "menopause between the ages of 40 and 44," while the FSH recommendation covers people "aged 40 to 45" (NICE NG23). Someone of 45 is outside NICE's definition of early menopause and still inside the band where FSH can be considered. Neither edge is a biological line; both are places where guidance has to pick a number.

NICE also closes off the alternatives at 45 and over, naming six tests that should not be used to identify perimenopause or menopause in that group: anti-Müllerian hormone, inhibin A, inhibin B, oestradiol, antral follicle count and ovarian volume (NICE NG23, 1.3.4).

Those are UK rules. US federal sources reach the same practical place by a looser route: the Office on Women's Health says a provider may test hormone levels "if your periods stop at an early age (before 40)" and that providers "don't usually recommend this test unless there is a medical reason to do so," because levels "go up and down in an unpredictable way" during the transition (OWH). On its early-menopause page the same body says that for menopause before 40, and for menopause between 40 and 45, a provider "may give you a blood test to measure estrogen and related hormones" (OWH). What no US federal source I could find does is set an age threshold the way NICE does, with testing advised against above it.

Above 45 you are in the ordinary window. Most women begin the transition between ages 45 and 55 (NIA), and that is exactly where a hormone level stops earning its keep. The perimenopause age range covers the timing question properly.

When testing genuinely is worth doing

Under 40 the picture changes completely, and this is the part worth acting on. Periods that stop early point at a different diagnosis with different consequences: OWH notes a higher risk of "serious health problems, such as heart disease and osteoporosis," alongside the early loss of fertility (OWH).

The NIA flags the trigger: "in some cases, for example if a woman's periods stopped at an early age, a doctor may suggest a blood test to check hormone levels" (NIA). For a woman under 40 with irregular periods, or none for four months or longer, NICHD describes a workup including a pregnancy test, a physical exam and bloods (NICHD).

Then the detail that reframes all of it: even where FSH is diagnostic, it is never read once. Four sources say so, and they differ only in the interval they specify.

Four to six weeks, a month, a month, a month: the exact interval is not standardised, and not one of them accepts a single reading. NICE states the consequence in its own sentence, quoted above. The one situation where an FSH result carries diagnostic weight is also the one where every source insists you repeat it, which tells you what a lone reading is worth everywhere else.

ACOG adds a condition that matters for anyone on hormonal medication: gonadotropin and estradiol values "may be altered by concomitant use of hormonal preparations and thus should only be obtained in patients who are not taking hormonal medications, including OCs" (ACOG, Committee Opinion 605). The committee opinion is dated July 2014 and was reaffirmed in 2025.

If you use hormonal contraception, a coil, or had a hysterectomy

The method that hides your periods usually hides the answer as well, and the blood test that looks like the obvious workaround is specifically ruled out. The FSRH puts the scale of it plainly: "Most women using hormonal contraception will have altered bleeding patterns or amenorrhoea and as a result it can be difficult to give accurate advice regarding underlying menopausal status" (FSRH).

Which methods remove the signal. The NHS lists the progestogen-only pill, the IUS (hormonal coil), the implant and the injection as methods that "can make periods irregular or stop completely," and notes that "the combined pill causes monthly bleeds like a period for as long as you take it" (NHS). A withdrawal bleed on the pill is not a cycle you can measure. NICE puts the general version of this to clinicians: "Take into account that it can be difficult to identify menopause in people who are taking hormonal treatments, for example, for the treatment of heavy menstrual bleeding" (NICE NG23, 1.3.2).

Why a blood test doesn't rescue it. NICE is direct: "Do not use a follicle-stimulating hormone (FSH) blood test to identify menopause in people using combined oestrogen and progestogen contraception or high-dose progestogen" (NICE NG23, 1.3.5). The FSRH explains the mechanism for combined hormonal contraception: those users have "very suppressed levels of estradiol, FSH and LH even if measured during the HFI" — the hormone-free interval — "so these cannot be used to inform advice regarding menopausal status" (FSRH). ACOG reaches the same place from the US side, although in a different context: writing about suspected primary ovarian insufficiency, it advises that gonadotropin and estradiol values be obtained only in patients who are not taking hormonal medications, oral contraceptives included (ACOG, Committee Opinion 605).

The combined pill hides the symptoms too. This is the part that catches people out, because it means both halves of the usual answer go missing at once. The FSRH states that "menopausal symptoms will be suppressed by the EE contained within CHC" — ethinylestradiol, the estrogen in most combined pills (FSRH). Feeling fine on the pill at 49 is not evidence that nothing is happening.

Non-hormonal methods change nothing. A copper coil, condoms or sterilisation leave the picture intact, and the FSRH says so plainly: "Women using non-hormonal contraception will experience the symptoms and signs of menopause in the same way as women not using any contraception" (FSRH). If your IUD is the copper one, the self-check above works normally. The two devices are often both called "the coil," and only one of them is a problem here.

After a hysterectomy or endometrial ablation. The bleeding signal is gone permanently, and STRAW+10 is unambiguous that these women "cannot be staged by menstrual bleeding criteria," with reproductive stage assessable only through "the endocrine markers of ovarian aging" (Harlow et al., 2012). The ovaries, if they were left in place, carry on regardless. There is a recognised route, and it is not a test: NICE tells clinicians to identify menopause in people who have had a hysterectomy "based on the type and combination of symptoms they have (for example, vasomotor symptoms)" (NICE NG23, 1.3.1).

What the self-check becomes in all these cases is a symptom record with dates rather than a cycle record, and the FSRH's general advice points the same way: "blood tests are not routinely needed to diagnose menopause," and clinicians "should focus on a woman's symptoms and needs rather than FSH levels unless they are concerned about premature menopause" (FSRH).

One narrow exception to all of this does exist, and it belongs to a different decision: when to stop contraception, not whether you are in perimenopause. The FSRH restricts FSH measurement for that purpose to a specific group, with conditions attached, and why FSH can't tell you when to stop contraception sets out the rule and the age thresholds in full. Two things are worth carrying over here. The FSRH says isolated estradiol, FSH and LH levels during perimenopause "can be misleading and should not be used as a basis for providing advice about stopping contraception," because ovulation may still occur. And the FDA says of home kits: "Do not use these tests to determine if you are fertile or can become pregnant" (FDA).

Sources differ on how to frame testing and fertility, and the difference is one of purpose rather than of fact. OWH tells readers that a blood test is available and that "you may choose to get tested if you want to know whether you can still get pregnant" (OWH). The FSRH's rule is about what a result may be used to decide. Wanting to know is not the same as being able to act on the number, and it is the acting that the FSRH rules out.

At-home kits and free online tests

Home menopause tests are urine FSH tests, and the fairest thing to say is that they do the job they were built for. The FDA's guidance rates them as accurate: "These tests will accurately detect FSH about 9 out of 10 times." The very next sentence is the one that matters: "This test does not detect menopause or perimenopause" (FDA).

Accuracy and relevance are different properties, and the regulator rather than a competitor is making the distinction. What you are buying is "a qualitative test — you find out whether or not you have elevated FSH levels, not if you definitely are in menopause or perimenopause" (FDA).

Both directions of result come with a caveat. The FDA lists what a reading depends on, including whether you "use, or recently stopped using, oral or patch contraceptives, hormone replacement therapy, or estrogen supplements," which covers anyone using the methods described in the section above. And a negative result settles nothing either: "You should not assume that a negative test means you have not reached menopause, there could be other reasons for the negative result" (FDA).

One warning has real consequences: a positive result is not a contraceptive decision. "Do not stop taking contraceptives based on the results of these tests because they are not foolproof and you could become pregnant" (FDA). Pregnancy remains possible throughout perimenopause, and the NIA advises continuing birth control for a full 12 months after your last period (NIA) — the same 12 months that, under STRAW+10, still count as part of perimenopause (Harlow et al., 2012).

The FDA's closing observation is the useful one: some home tests are identical to your doctor's, but "doctors would not use this test by itself" (FDA). That page is dated 27 September 2018; the products have changed since, the limitation has not.

Free online tests and quizzes are a different product with the same gap. They are symptom checklists, and no guideline read for this page recommends any questionnaire for identifying perimenopause: NICE's recommendations rest on age, symptoms and cycle history, and name none. The research literature does contain validated instruments, and what their authors built them for is the point:

• The Menopause Rating Scale was designed "to assess symptoms/complaints of aging women under different conditions," "to evaluate the severity of symptoms over time," and to measure change before and after hormone therapy (Heinemann K, Ruebig A, Potthoff P, et al. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes 2004;2:45).
• MENQOL is described by its authors as an instrument that "functions well in differentiating between women according to their quality of life and in measuring changes in their quality of life" (Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24(3):161–75).
• The Greene climacteric scale was built to be "a standard measure of core climacteric symptoms" (Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29(1):25–31).

Severity, quality of life, symptom measurement. None of the three was built to tell you whether you are in the transition, and the unvalidated quizzes that borrow their format cannot do more than the instruments they imitate.

Saliva and urine hormone panels sold direct to the public are weaker again. ACOG states that "currently, there are no FDA-approved salivary or urinary tests for steroid hormone measurement," and that salivary testing "does not offer accurate or precise assessment of hormone levels" (ACOG Clinical Consensus No. 6). The Menopause Society's position statement says salivary and urine hormone testing "to determine dosing are unreliable and not recommended" (The Menopause Society, 2022). Read both precisely: each is about setting a dose of hormone therapy, not about diagnosing anything. They are strong evidence that these panels cannot guide treatment, and the diagnosis point is carried by NICE and OWH instead.

An ACOG piece from November 2024 adds a shopping note. Its third rule is "watch out for marketing buzzwords," and the first example given is "hormone balance or imbalance," on the grounds that "your body balances your hormones for you, even as they fluctuate during the menopause transition." It also advises checking who is selling: a doctor with a financial interest in the product being recommended has a conflict of interest (Santoro, ACOG).

Tests that rule something else out

Diagnosing perimenopause and excluding other explanations are two separate investigations, and the second is often the more useful one, because the alternatives are treatable. Cleveland Clinic's advice is to describe what you are experiencing to a provider so they can confirm the symptoms are perimenopause "and not another health condition" (Cleveland Clinic). What that involves depends on your age and symptoms, so the choice belongs to a clinician rather than to a web page. The conditions a clinician may want to rule out first covers what each of those tests is actually looking for, and which symptoms point where.

What to ask your doctor

Five questions worth raising:

• Does this pattern fit the menopausal transition, given my age? The actual diagnostic question, answerable from your cycle record and history.
• Is there anything else worth ruling out? The separate investigation described above, and the one more likely to change your treatment.
• Would a hormone test change what we do next? Worth asking directly. If the answer is no, that is useful information about the test.
• My contraception hides my periods — what are we using instead? The symptom record, the timeline and your age, rather than a bleeding pattern that the method is producing.
• What are the options if symptoms are affecting daily life? Perimenopause being normal doesn't mean the symptoms have to be endured untreated.

For a clinician with specific training here, ACOG points to the letters MSCP after a provider's name, standing for Menopause Society Certified Practitioner (Santoro, ACOG). Afterwards, the code that turns up on your notes or your claim will most likely be N95.1, “Menopausal and female climacteric states”, because no ICD-10-CM code is actually named perimenopause — what that code does and does not cover explains the mismatch. For the overview this page sits under, what perimenopause actually is covers the transition from start to finish, and how long perimenopause lasts answers what usually comes next.

Common questions about perimenopause testing (FAQ)

Is there a test for perimenopause? Not at 45 and over. NICE tells clinicians to identify perimenopause "without laboratory tests" in otherwise healthy people aged 45 or over with recently started vasomotor symptoms and any change in their menstrual cycle (NICE NG23, 1.3.1). Cleveland Clinic gives the reason: "hormone testing isn't necessary to diagnose perimenopause" because "hormone levels fluctuate so much that the tests aren't reliable" (Cleveland Clinic). Age, symptoms and cycle history do the work instead.

Do at-home menopause tests work? They measure what they claim to, which is not the same as answering your question. The FDA says these urine tests "will accurately detect FSH about 9 out of 10 times," then states directly: "This test does not detect menopause or perimenopause." The same page tells you not to stop contraception on the strength of a result, and not to "use these tests to determine if you are fertile or can become pregnant" (FDA).

How can I check while I'm on the pill or have a coil? Not from your bleeding pattern, and not from a blood test either. NICE instructs: "Do not use a follicle-stimulating hormone (FSH) blood test to identify menopause in people using combined oestrogen and progestogen contraception or high-dose progestogen" (NICE NG23, 1.3.5). The NHS lists the progestogen-only pill, the hormonal coil, the implant and the injection as methods that can stop or disrupt periods (NHS), and the FSRH adds that the combined pill suppresses menopausal symptoms as well. A copper coil or any other non-hormonal method changes nothing: the FSRH says those users "will experience the symptoms and signs of menopause in the same way as women not using any contraception" (FSRH). What replaces the cycle record is a dated symptom record.

Is it a hormone imbalance or perimenopause? "Hormone imbalance" is not a diagnosis. ACOG lists it first among the menopause marketing buzzwords to watch out for, with the comment that "your body balances your hormones for you, even as they fluctuate during the menopause transition" (Santoro, ACOG). Perimenopause is a named transition with published criteria. The conditions that genuinely produce overlapping symptoms have names and tests of their own, and what "hormone imbalance" lists usually describe traces where the best-known list came from and what it was actually about.

What FSH level indicates perimenopause? There is no FSH number you can apply to yourself, and the three numbers in circulation belong to three different decisions. STRAW+10 publishes a level "greater than 25 IU/L in a random blood draw" as characteristic of the late transition only, cautioning that the appropriate value depends on the assay a laboratory uses and still requires empirical confirmation (Harlow et al., 2012). The FSRH, writing about when contraception can stop, treats a level above 30 IU/L as indicating "a degree of ovarian insufficiency, but not necessarily sterility" (FSRH). ACOG, investigating primary ovarian insufficiency under 40, puts the menopausal range at "greater than 30–40 mIU/mL, depending on the laboratory used" (ACOG, Committee Opinion 605). None of the three is a self-diagnosis threshold.

Medical disclaimer: This article is for informational purposes only. Always consult a qualified healthcare provider before making changes to your health routine.

Sources

1. National Institute for Health and Care Excellence. Menopause: identification and management. NICE guideline NG23, published 12 November 2015, last updated 15 April 2026 — Clinical guideline. https://www.nice.org.uk/guidance/ng23/chapter/Recommendations
2. Cleveland Clinic. Perimenopause — Health system disease reference. https://my.clevelandclinic.org/health/diseases/21608-perimenopause
3. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause, 2012;19(4) — Peer-reviewed journal article via PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC3340903/
4. National Institute on Aging (NIH). What Is Menopause? — Government health information. https://www.nia.nih.gov/health/menopause/what-menopause
5. Office on Women's Health, US Department of Health and Human Services. Menopause basics — Government health information, page last updated 2 April 2026. https://womenshealth.gov/menopause/menopause-basics
6. Office on Women's Health, US Department of Health and Human Services. Early or premature menopause — Government health information, page last updated 11 March 2025. https://womenshealth.gov/menopause/early-or-premature-menopause
7. NHS. Menopause and perimenopause — Symptoms — Public health service information, page last reviewed 19 May 2026. https://www.nhs.uk/conditions/menopause-and-perimenopause/symptoms/
8. Faculty of Sexual & Reproductive Healthcare. Contraception for Women Aged Over 40 Years. August 2017, amended May 2025 — Clinical guideline (PDF). https://www.cosrh.org/Common/Uploaded%20files/documents/fsrh-guideline-contraception-for-women-aged-over-40-years.pdf
9. US Food and Drug Administration. Home Use Tests: Menopause — Federal regulator device information, content current as of 27 September 2018. https://www.fda.gov/medical-devices/home-use-tests/menopause
10. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, NIH). How do healthcare providers diagnose POI? — Government health information. https://www.nichd.nih.gov/health/topics/poi/conditioninfo/diagnosed
11. American College of Obstetricians and Gynecologists. Primary Ovarian Insufficiency in Adolescents and Young Women. Committee Opinion No. 605, July 2014, reaffirmed 2025 — Clinical guidance. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2014/07/primary-ovarian-insufficiency-in-adolescents-and-young-women
12. American College of Obstetricians and Gynecologists. Compounded Bioidentical Menopausal Hormone Therapy. Clinical Consensus No. 6, November 2023 — Clinical guidance. https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/11/compounded-bioidentical-menopausal-hormone-therapy
13. The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29(7):767–794. doi:10.1097/GME.0000000000002028 — Professional society position statement (PDF). https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf
14. Santoro N. Menopause Misinformation Is Everywhere. Here's How to Detect It. American College of Obstetricians and Gynecologists, November 2024 — Expert commentary. https://www.acog.org/womens-health/experts-and-stories/the-latest/menopause-misinformation-is-everywhere-heres-how-to-detect-it
15. Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F, Heinemann LA, Do MT. The Menopause Rating Scale (MRS) scale: a methodological review. Health and Quality of Life Outcomes, 2004;2:45 — Peer-reviewed journal article. https://pubmed.ncbi.nlm.nih.gov/15345062/
16. Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E, Guyatt GH, Norton PG, Dunn E. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas, 1996;24(3):161–75 — Peer-reviewed journal article. https://pubmed.ncbi.nlm.nih.gov/8844630/
17. Greene JG. Constructing a standard climacteric scale. Maturitas, 1998;29(1):25–31 — Peer-reviewed journal article. https://pubmed.ncbi.nlm.nih.gov/9643514/

All sources accessed 8 October 2026.

Claire Whitfield

Women's Health Specialist

A women's health specialist who checks what a test actually measures before asking what it can prove.

View profileView Xing profile